欧洲泌尿外科学会上尿路尿路上皮癌指南:2023年更新
欧洲泌尿外科学会上尿路尿路上皮癌指南小组更新指南,以协助临床医生进行循证管理。推荐基于对PubMed、Ovid、EMBASE和Cochrane数据库的系统文献检索,由专家组评估。低风险上尿路尿路上皮癌且双肾有功能的患者应提供保留肾脏的管理作为主要治疗选择;高风险患者可选根治性肾输尿管切除术后铂类化疗,不适合或拒绝化疗者可选纳武利尤单抗辅助治疗;转移性疾病中,不适合顺铂者推荐吉西他滨/卡铂一线治疗,PD-1/PD-L1阳性肿瘤患者应提供检查点抑制剂(帕博利珠单抗或阿替利珠单抗)。
要点
- 低风险上尿路尿路上皮癌且双肾有功能的患者,应提供保留肾脏的管理作为主要治疗选择。
- 高风险上尿路尿路上皮癌患者,根治性肾输尿管切除术后铂类化疗是选项;不适合或拒绝化疗者可选纳武利尤单抗辅助治疗。
- 转移性疾病中,不适合顺铂者推荐吉西他滨/卡铂一线治疗;PD-1/PD-L1阳性肿瘤患者应提供检查点抑制剂(帕博利珠单抗或阿替利珠单抗)。
核心结论
- 指南包含根据当前最佳证据管理个体患者的信息,泌尿外科医生应根据肿瘤风险分层并考虑每位患者的具体临床特征来确定最佳治疗方案。
- 尽管数据正在积累,许多领域仍缺乏高级别证据以提供强烈推荐。
- 根据组织学和临床检查(包括影像)进行患者分层以及评估Lynch综合征风险患者将有助于管理。
研究设计与样本
- 欧洲泌尿外科学会上尿路尿路上皮癌指南小组更新的指南,推荐基于对PubMed、Ovid、EMBASE和Cochrane数据库的系统文献检索,结果由专家组评估。
主要发现
- 低风险上尿路尿路上皮癌且双肾有功能的患者应提供保留肾脏的管理作为主要治疗选择。
- 高风险上尿路尿路上皮癌患者,根治性肾输尿管切除术后铂类化疗以及不适合或拒绝化疗患者的纳武利尤单抗辅助治疗是选项。
- 转移性疾病中,吉西他滨/卡铂化疗推荐为不适合顺铂患者的一线治疗。
- PD-1/PD-L1阳性肿瘤患者应提供检查点抑制剂(帕博利珠单抗或阿替利珠单抗)。
关键数值与推荐
- 低风险上尿路尿路上皮癌且双肾有功能的患者:保留肾脏的管理应作为主要治疗选择提供。
- 高风险上尿路尿路上皮癌:根治性肾输尿管切除术后铂类化疗是选项;不适合或拒绝化疗者可选纳武利尤单抗辅助治疗。
- 转移性疾病、不适合顺铂患者:推荐吉西他滨/卡铂化疗作为一线治疗。
- PD-1/PD-L1阳性肿瘤患者:应提供检查点抑制剂(帕博利珠单抗或阿替利珠单抗)。
临床怎么用
- 泌尿外科医生应根据肿瘤风险分层并考虑每位患者的具体临床特征来确定最佳治疗方案。
- 根据组织学和临床检查(包括影像)进行患者分层以及评估Lynch综合征风险患者将有助于管理。
局限性
- 尽管数据正在积累,许多领域仍缺乏高级别证据以提供强烈推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in these guidelines are based on a review of the literature via a systematic search of the PubMed, Ovid, EMBASE, and Cochrane databases. Data were searched using the following keywords: urinary tract cancer, urothelial carcinomas, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, (neo)adjuvant treatment, instillation, recurrence, risk factors, metastatic, immunotherapy, and survival. The results were assessed by a panel of experts. EVIDENCE SYNTHESIS: Even though data are accruing, for many areas there is still insufficient high-level evidence to provide strong recommendations. Patient stratification on the basis of histology and clinical examination (including imaging) and assessment of patients at risk of Lynch syndrome will aid management. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk UTUC and two functional kidneys. In particular, for patients with high-risk or metastatic UTUC, new treatment options have become available. In high-risk UTUC, platinum-based chemotherapy after radical nephroureterectomy, and adjuvant nivolumab for unfit or patients who decline chemotherapy, are options. For metastatic disease, gemcitabine/carboplatin chemotherapy is recommended as first-line treatment for cisplatin-ineligible patients. Patients with PD-1/PD-L1-positive tumours should be offered a checkpoint inhibitor (pembrolizumab or atezolizumab). CONCLUSIONS: These guidelines contain information on the management of individual patients according to the current best evidence. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen according to the risk stratification of these tumours. PATIENT SUMMARY: Cancer of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, timely and appropriate diagnosis is most important. A number of known risk factors exist.
引用
- Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023. PMID: 36967359. doi:10.1016/j.eururo.2023.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。